Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Response to Letter].

Qin X, Jiang H, Xie Y, Liu Q, Zhang Y, Mamtili I

Open source

DOI
10.2147/dddt.s652138
Published
2026
Container
Drug design, development and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/dddt.s652138,
  title = {Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Response to Letter].},
  author = {Qin X and Jiang H and Xie Y and Liu Q and Zhang Y and Mamtili I},
  year = {2026},
  journal = {Drug design, development and therapy},
  doi = {10.2147/dddt.s652138},
  url = {https://doi.org/10.2147/dddt.s652138}
}

RIS

TY  - JOUR
TI  - Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Response to Letter].
AU  - Qin X
AU  - Jiang H
AU  - Xie Y
AU  - Liu Q
AU  - Zhang Y
AU  - Mamtili I
PY  - 2026
JO  - Drug design, development and therapy
DO  - 10.2147/dddt.s652138
UR  - https://doi.org/10.2147/dddt.s652138
ER  - 

APA

X, Q., H, J., Y, X., Q, L., Y, Z., & I, M. (2026). Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Response to Letter].. Drug design, development and therapy. https://doi.org/10.2147/dddt.s652138

Source records